Premium
Botulinum toxin type A: new therapeutic directions
Author(s) -
Guyer Barry M.
Publication year - 1999
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.1999.tb00029.x
Subject(s) - medicine , botulinum toxin , hyperhidrosis , cervical dystonia , cerebral palsy , intensive care medicine , physical medicine and rehabilitation , surgery
Intramuscular injections of botulinum toxin type A (BTX‐A) have been used successfully to treat disorders such as cerebral palsy and cervical dystonia for many years. New and exciting directions for the toxin are currently under clinical investigation for a number of unlicensed indications including tension‐type headache, myofascial pain and hyperhidrosis. Although research on BTX‐A is prolific, there is still much to be learnt regarding the toxin's mode of action, clinical application and perhaps more importantly, its place in the overall treatment strategy implemented by physicians to ensure treatment is a success for both the patient and the physician. This review will focus on these issues, by outlining some of the future directions for BTX‐A research.